The Impact of COVID-19 on Individuals with Intellectual and Developmental Disabilities: Clinical and Scientific Priorities

John N. Constantino; Mustafa Sahin; Joseph Piven; Rylin Rodgers; John Tschida

doi:10.1176/appi.ajp.2020.20060780

The Impact of COVID-19 on Individuals with Intellectual and Developmental Disabilities: Clinical and Scientific Priorities

John N. Constantino, Mustafa Sahin, Joseph Piven, Rylin Rodgers, John Tschida

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1091-1093
Number of pages	3
Journal	American Journal of Psychiatry
Volume	177
Issue number	11
DOIs	https://doi.org/10.1176/appi.ajp.2020.20060780
State	Published - Nov 2020

Access to Document

10.1176/appi.ajp.2020.20060780

Cite this

@article{4d4a13da6deb44fd9258eb2acb84797c,

title = "The Impact of COVID-19 on Individuals with Intellectual and Developmental Disabilities: Clinical and Scientific Priorities",

author = "Constantino, {John N.} and Mustafa Sahin and Joseph Piven and Rylin Rodgers and John Tschida",

note = "Funding Information: Dr. Sahin has received grant support from Astellas, Biogen, the Boston Children{\textquoteright}s Hospital Intellectual and Developmental Disabilities Research Center, Bridgebio, the Developmental Synaptopathies Consortium, Ipsen, LAM Therapeutics, Novartis, Pfizer, Quadrant Biosciences, and Roche, and he has served on scientific advisory boards for Aeovian, Celgene, Regenxbio, Roche, Sage, and Takeda. The other authors report no financial relationships with commercial interests.",

year = "2020",

month = nov,

doi = "10.1176/appi.ajp.2020.20060780",

language = "English",

volume = "177",

pages = "1091--1093",

journal = "American Journal of Psychiatry",

issn = "0002-953X",

number = "11",

}

TY - JOUR

T1 - The Impact of COVID-19 on Individuals with Intellectual and Developmental Disabilities

T2 - Clinical and Scientific Priorities

AU - Constantino, John N.

AU - Sahin, Mustafa

AU - Piven, Joseph

AU - Rodgers, Rylin

AU - Tschida, John

N1 - Funding Information: Dr. Sahin has received grant support from Astellas, Biogen, the Boston Children’s Hospital Intellectual and Developmental Disabilities Research Center, Bridgebio, the Developmental Synaptopathies Consortium, Ipsen, LAM Therapeutics, Novartis, Pfizer, Quadrant Biosciences, and Roche, and he has served on scientific advisory boards for Aeovian, Celgene, Regenxbio, Roche, Sage, and Takeda. The other authors report no financial relationships with commercial interests.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85092449384&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2020.20060780

DO - 10.1176/appi.ajp.2020.20060780

M3 - Letter

C2 - 32854530

AN - SCOPUS:85092449384

SN - 0002-953X

VL - 177

SP - 1091

EP - 1093

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

IS - 11

ER -

The Impact of COVID-19 on Individuals with Intellectual and Developmental Disabilities: Clinical and Scientific Priorities

Access to Document

Other files and links

Cite this